ライフサイエンスコーパス: urticaria

1 rgic urticaria, solar urticaria, or pressure urticaria).

2 be useful for assessment of the activity of urticaria.

3 insect venom-, and drug allergy and chronic urticaria.

4 urticaria, contact urticaria, and aquagenic urticaria.

5 EMA) for the treatment of chronic idiopathic urticaria.

6 atients with antihistamine-resistant chronic urticaria.

7 tic approaches for the different subtypes of urticaria.

8 nd has shown efficacy in chronic spontaneous urticaria.

9 cond case is a man in his 20s with recurrent urticaria.

10 CT items tested in 508 patients with chronic urticaria.

11 trates are seen in a subset of patients with urticaria.

12 arily mild to moderate allergic rhinitis and urticaria.

13 nd to antihistamines and other treatments of urticaria.

14 n reason for recurrent wheals is spontaneous urticaria.

15 ents for allergic and infectious triggers of urticaria.

16 pathophysiology, diagnosis and treatment of urticaria.

17 tiologies prior to a diagnosis of idiopathic urticaria.

18 phylaxis, systemic conditions and autoimmune urticaria.

19 ction site reactions, fussiness, rashes, and urticaria.

20 pathic, urticaria and one with acquired cold urticaria.

21 sfully except in cases of chronic idiopathic urticaria.

22 ases Muckle-Wells syndrome and familial cold urticaria.

23 eventually diagnosed with chronic idiopathic urticaria.

24 pain, tachycardia, hypertension, fever, and urticaria.

25 I fever, asthenia, chills, nausea, rash, and urticaria.

26 bratory angioedema and aquagenic and contact urticaria.

27 rom disease, and 10 with chronic spontaneous urticaria.

28 tic dermographism, cold urticaria, and solar urticaria.

29 body, effectively treats chronic spontaneous urticaria.

30 s (3.9%) had a history of idiopathic chronic urticaria.

31 ssing QOL in pediatric patients with chronic urticaria.

32 activation release mediators responsible for urticaria.

33 and inactive urticaria, and 7 cases of acute urticaria.

34 It encompasses spontaneous and inducible urticarias.

35 ) stimuli underlie the pathology of physical urticarias.

36 cne vulgaris, 0.19% for psoriasis, 0.19% for urticaria, 0.16% for viral skin diseases, 0.15% for fung

37 3.1 for hypersensitivity reactions; 2.6 for urticaria; 0.2 for venous thromboembolic events, autoimm

38 laxis, 84.0 (SD 13.6) in seven patients with urticaria, 142.0 (SD 24.0) in two patients with eczema,

39 iagnosis and management of acute and chronic urticaria: 2014 update." This is a complete and comprehe

40 Among 386 patients diagnosed as spontaneous urticaria, 284 patients (73.6%) had begun treatments wit

41 ort comprised 18 cases of chronic and active urticaria, 7 cases of chronic and inactive urticaria, an

42 phenotypes, all of whom had evaporative cold urticaria, 8 patients had a history of unique neonatal-o

43 C-reactive protein correlated with urticaria activity (P < .001), quality of life impairmen

44 The urticaria activity score (UAS) is the gold standard for

45 UAS7, weekly total values of the Urticaria Activity Score (UAS), has correlation with Der

46 defined as well-controlled urticaria (weekly Urticaria Activity Score [UAS7] </= 6) or complete respo

47 on with disease activity, as assessed by the urticaria activity score and with reduced basophil count

48 sponse after retreatment was assessed by the urticaria activity score in patients with chronic sponta

49 s of patients with well-controlled symptoms (urticaria activity score over 7 days (UAS7) 6: 51.9% vs.

50 mplete response, were assessed by use of the urticaria activity score, physician and patient visual a

51 iable tool to assess disease activity is the Urticaria Activity Score, which prospectively documents

52 te-to-severe disease activity as reported by Urticaria Activity Score.

53 Efficacy (itch severity, hive, and urticaria activity scores) was evaluated at weeks 12 and

54 ert (Alza Corp., Palo Alto, CA), generalized urticaria after a single application of 1% cyclopentolat

55 (P=.001), and those who experienced isolated urticaria after NSAID intake (P=.024).

56 ued because of a drug-related adverse event (urticaria) after week 24.

57 azard ratio [aHR], 2.49; 95% CI, 1.93-3.21), urticaria (aHR, 1.32; 95% CI, 1.00-1.74), or asthma (aHR

58 eport on physical urticarias and cholinergic urticaria (Allergy, 2009).

59 Many patients with chronic idiopathic urticaria (also called chronic spontaneous urticaria) do

60 ne and levocetirizine in chronic spontaneous urticaria and against histamine-induced weal and flare r

61 IgE-mediated reactions (urticaria and anaphylaxis) were seen in 15%.

62 for the management of patients with chronic urticaria and angioedema has been prepared by the Standa

63 Patient-reported data on urticaria and angioedema symptoms, HRQoL, and work produ

64 Urticaria and angioedema were not reported as symptoms i

65 /angioedema (NIUA), and single NSAID-induced urticaria and angioedema.

66 l approach to the patient with NSAID-induced urticaria and angioedema.

67 atient 2, a 24-year-old woman, was seen with urticaria and associated joint pain and swelling.

68 atient 1, a 47-year-old woman, was seen with urticaria and associated night sweats, fevers, and polya

69 , and chronic inflammatory diseases, such as urticaria and asthma.

70 y score in patients with chronic spontaneous urticaria and by trigger threshold testing (in patients

71 Two developed urticaria and one developed urticaria and dyspnea.

72 nder and Alternaria tenuis with a history of urticaria and dyspnoea after drinking beer and a weak sk

73 E mAb, for patients with chronic spontaneous urticaria and for the clinical benefit of patients with

74 identified in individuals with cold-induced urticaria and immune dysregulation PLCG2 exon-skipping m

75 Two developed urticaria and one developed urticaria and dyspnea.

76 t year; one dealing with chronic idiopathic, urticaria and one with acquired cold urticaria.

77 Chronic spontaneous urticaria and other chronic forms of urticaria do not on

78 dance with special sections on children with urticaria and the use of antihistamines in women who are

79 he skin of patients with chronic spontaneous urticaria and was released from isolated basophils follo

80 aminergic angioedema generally presents with urticaria and/or pruritus and will respond to convention

81 te our previous consensus report on physical urticarias and cholinergic urticaria (Allergy, 2009).

82 e urticaria, 7 cases of chronic and inactive urticaria, and 7 cases of acute urticaria.

83 y angioedema, cholinergic urticaria, contact urticaria, and aquagenic urticaria.

84 Additionally, contact dermatitis, urticaria, and drug reactions are addressed in this revi

85 Urticaria, and especially chronic spontaneous urticaria

86 ractable neuropathic pain, grade 3 recurrent urticaria, and grade 4 vomiting.

87 of biologics to manage uncontrolled asthma, urticaria, and nasal polyposis.

88 es of 3F8 treatment were severe pain, fever, urticaria, and reversible decreases in blood counts and

89 trongest for symptomatic dermographism, cold urticaria, and solar urticaria.

90 type I immediate hypersensitivity reactions (urticaria, angioedema, anaphylaxis, and allergic rhiniti

91 Novel pathogenic insights, for example, into urticaria, angioedema, mastocytosis, led to the developm

92 Multiple NSAID-induced urticaria/angioedema (MNSAID-UA) is an entity well diffe

93 persensitivity reactions, with NSAID-induced urticaria/angioedema (NIUA) being the most frequent clin

94 of drug hypersensitivity with NSAIDs-induced urticaria/angioedema (NIUA) the most common phenotype.

95 nonsteroidal anti-inflammatory drug-induced urticaria/angioedema (NIUA), and single NSAID-induced ur

96 -specific IgE antibody production leading to urticaria/angioedema and rarely to anaphylaxis.

97 Nonsteroidal anti-inflammatory drugs-induced urticaria/angioedema does not seem to precede the onset

98 t often manifested as rhinitis and asthma or urticaria/angioedema induced by cross-reacting nonsteroi

99 Absence of urticaria/angioedema is an indicator of severe anaphylax

100 The absence of urticaria/angioedema is significantly related to BST ele

101 (ii) patients with more than two episodes of urticaria/angioedema to a single NSAID with good toleran

102 : initial reaction characteristics (isolated urticaria/angioedema vs other presentations), baseline e

103 Among patients with urticaria/angioedema, 13 patients (3.9%) had a history o

104 subjects were assessed; 217 had histories of urticaria/angioedema, 50 of anaphylaxis, 26 of nonimmedi

105 antibodies to the drug (single NSAID-induced urticaria/angioedema, SNIUA), and (iii) controls who tol

106 dominantly inherited complex of cold-induced urticaria, antibody deficiency, and susceptibility to in

107 east a subset of cases of chronic idiopathic urticaria are autoimmune in origin.

108 initis, atopic dermatitis, food allergy, and urticaria are common in general pediatric practice.

109 dermatitis, allergic contact dermatitis, and urticaria are very common.

110 ders, such as contact dermatitis and chronic urticaria, are characterized by inflammation involving m

111 els (P = .03) but only rarely had angioedema/urticaria associated with hypotension (P = .004).

112 ome was occurrence of at least 1 AM (eczema, urticaria, asthma, and rhinoconjunctivitis).

113 utropenia, and somnolence at 40 mg/m(2); and urticaria at 55 mg/m(2).

114 s anaphylaxis, food allergy, rhinitis, itch, urticaria, atopic dermatitis, and asthma.

115 The present review serves to address urticaria - both acute and chronic - as well as the diff

116 ommend assessing disease activity in chronic urticaria by using UAS.

117 Due to the myriad of triggers that may cause urticaria, careful individualized patient assessment is

118 Cold contact urticaria (CCU) is characterized by itchy wheal and flar

119 74 years; 18 women) with chronic spontaneous urticaria, chronic inducible urticaria, or both who show

120 Patients with chronic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU) often

121 iagnosis and management of chronic inducible urticaria (CIndU) extend, revise and update our previous

122 s lacking in patients with chronic inducible urticarias (CIndUs), which are frequently H1-antihistami

123 The etiology of chronic idiopathic urticaria (CIU) is attributed to autoantibodies directed

124 d in approximately 40% of chronic idiopathic urticaria (CIU) patients.

125 patterns in patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) trea

126 nic idiopathic urticaria/chronic spontaneous urticaria (CIU/CSU) often continue to experience symptom

127 patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1 -a

128 ith chronic idiopathic urticaria/spontaneous urticaria (CIU/CSU) who remained symptomatic despite H1

129 The reported rate of urticaria comorbidity in PI patients in 18 independent s

130 urticaria, vibratory angioedema, cholinergic urticaria, contact urticaria, and aquagenic urticaria.

131 etrospectively assess urticaria control, the Urticaria Control Test (UCT).

132 outcome instrument to retrospectively assess urticaria control, the Urticaria Control Test (UCT).

133 urticaria was defined as 'chronic persistent urticaria' (CPU), while the presence of urticaria for 2-

134 ays a week was defined as 'chronic recurrent urticaria' (CRU).

135 ng weals in chronic spontaneous (idiopathic) urticaria (CSU) are incompletely understood.

136 Patients with chronic spontaneous urticaria (CSU) are widely held to often have other auto

137 Chronic spontaneous urticaria (CSU) can be debilitating, difficult to treat,

138 Chronic spontaneous urticaria (CSU) is a common skin disorder, but its clini

139 Chronic spontaneous urticaria (CSU) is a mast cell-driven skin disease chara

140 Chronic spontaneous urticaria (CSU) is defined as persistent wheals, angioed

141 Chronic spontaneous urticaria (CSU) is one of the most costly allergic condi

142 Chronic spontaneous urticaria (CSU) is the recurrence of urticaria without a

143 Chronic spontaneous urticaria (CSU) patients (n = 113) were treated with oma

144 quality of life (QoL) in chronic spontaneous urticaria (CSU) patients with angioedema refractory to h

145 The knowledge about chronic spontaneous urticaria (CSU) phenotypes is based on its clinical char

146 Chronic spontaneous urticaria (CSU) severely impacts quality of life (QoL),

147 Chronic spontaneous urticaria (CSU) significantly impacts the quality of lif

148 levels in patients with chronic spontaneous urticaria (CSU) suggest autoallergic mechanisms.

149 iopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) treated with omalizumab.

150 rticaria, and especially chronic spontaneous urticaria (CSU), is a difficult condition to treat.

151 nts given a diagnosis of chronic spontaneous urticaria (CSU), there are no obvious external triggers,

152 tients with a history of chronic spontaneous urticaria (CSU).

153 consistently reported in chronic spontaneous urticaria (CSU).

154 ctivity in patients with chronic spontaneous urticaria (CSU).

155 er and are classified as chronic spontaneous urticaria (CSU).

156 -tolerated treatment for chronic spontaneous urticaria (CSU).

157 with severity scores in chronic spontaneous urticaria (CSU); however, the role of filaggrin breakdow

158 Chronic urticaria (CU) affects 0.1% to 0.3% of children.

159 f NIUA has been suggested to lead to chronic urticaria (CU) in an important proportion of patients, s

160 Chronic urticaria (CU) is a common disease in which most cases w

161 Chronic urticaria (CU) is a disease characterized by pruritic we

162 Chronic urticaria (CU) is a frequent skin disease characterized

163 Chronic urticaria (CU) is a widespread skin disease, characteriz

164 Functional autoantibodies in chronic urticaria (CU) patient sera have been demonstrated again

165 those of other diseases, such as asthma and urticaria, current data suggest that its diagnosis is of

166 dU subtypes: symptomatic dermographism, cold urticaria, delayed-pressure urticaria, solar urticaria,

167 the 4-item UCT in 120 patients with chronic urticaria demonstrated that this new tool exhibits good

168 For children with chronic urticaria, determination of NSAID hypersensitivity in a

169 taneous urticaria and other chronic forms of urticaria do not only cause a decrease in quality of lif

170 c urticaria (also called chronic spontaneous urticaria) do not have a response to therapy with H-anti

171 Five patients had transient urticaria during infusions.

172 The most common ADEs (urticaria, dyspnea, vomiting, pruritus, facial edema, an

173 Headache, back pain, vasodilatation, and urticaria each occurred in 6% of patients.

174 g of erythritol induced remarkable coughing, urticaria, edema, wheezing and hypoxemia.

175 lysis, has been found to be increased during urticaria exacerbations; moreover, it has been proposed

176 titative real time PCR revealed that chronic urticaria expresses high levels of CRH-R1 and HDC as com

177 on adverse events included infections, rash, urticaria, fatigue, and pruritus.

178 Familial cold urticaria (FCU) and Muckle-Wells syndrome (MWS) are domi

179 Familial cold urticaria (FCU) is a rare autosomal dominant inflammator

180 MIM 120100), commonly known as familial cold urticaria (FCU), is an autosomal-dominant systemic infla

181 the past year, focusing primarily on asthma, urticaria, food allergy, and vaccine reactions.

182 tent urticaria' (CPU), while the presence of urticaria for 2-4 days a week was defined as 'chronic re

183 ectively documents the signs and symptoms of urticaria for several days.

184 d the patients who suffered from spontaneous urticaria for six weeks or longer at their first visit t

185 It is important to distinguish idiopathic urticaria from related conditions such as anaphylaxis, s

186 igher than those in the chronic and inactive urticaria group (p<0.01).

187 PTF1+2 levels in the acute urticaria group were higher than those in the chronic an

188 PTF1+2 levels in the chronic and active urticaria group were higher than those in the chronic an

189 Chronic urticaria has a significant impact on a patient's qualit

190 coagulation dysfunction and the pathology of urticaria has been reported, but research in children is

191 Chronic spontaneous urticaria has considerable humanistic and economic impac

192 Patients with autosomal dominant vibratory urticaria have localized hives and systemic manifestatio

193 urticaria, delayed-pressure urticaria, solar urticaria, heat urticaria, vibratory angioedema, choline

194 re neuropathic pain, fever, nausea/vomiting, urticaria, hypotension, mild to moderate capillary leak

195 of those with less severe disease, inducible urticarias, idiopathic histaminergic angio-oedema withou

196 Prognosis of spontaneous urticaria in association with early treatment remained u

197 Chronic urticaria in children is difficult to manage and there i

198 for the management of patients with chronic urticaria in clinical practice.

199 ts who are seen with antihistamine-resistant urticaria in combination with systemic inflammatory symp

200 no standard for assessing pediatric chronic urticaria in Japan.

201 cal symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despi

202 y studied the prognosis of acute spontaneous urticaria in relation to age and treatments in a local c

203 One case of urticaria in the vaccine group and one each of acute gas

204 onymous variant cosegregating with vibratory urticaria in two large kindreds.

205 asthma and/or atopy (hay fever and/or eczema/urticaria) in a historical cohort of students born befor

206 Urticaria including CSU is more prevalent in patients wi

207 Urticaria including CSU might be a quite common symptom

208 anagement approaches to treatment of chronic urticaria, including use of omalizumab, are being identi

209 Chronic urticaria is a common disorder characterized by recurren

210 Chronic urticaria is a frequent and debilitating skin disease.

211 Urticaria is a frequent, mast cell-driven disease, prese

212 The life-time prevalence for acute urticaria is approximately 20%.

213 An autoimmune subset of chronic spontaneous urticaria is increasingly being recognized international

214 n association with mastocytosis, asthma, and urticaria, is used in conjunction with stem cell factor

215 Chronic spontaneous urticaria markedly interfered with sleep and daily activ

216 luded pain, fever, nausea, emesis, diarrhea, urticaria, mild elevation of hepatic transaminases, capi

217 Patients with chronic urticaria more frequently had seropositivity of fasciolo

218 e in other indications such as acquired cold urticaria, mosquito bite allergy and mastocytosis.

219 Thirty-one patients (20%) had inducible urticaria, most commonly cold induced.

220 and the Muckle-Wells syndrome/familial cold urticaria (MWS/FCU) locus on distal chromosome 1q44.

221 neutropenia (n = 2), hemorrhage (n = 3), and urticaria (n = 1).

222 Adverse effects to aspirin included urticaria (n=177, 53.6%), angioedema (n=69, 20.9%), asth

223 l asthma, atopic dermatitis, food allergies, urticaria, nonhereditary angioedema, systemic anaphylaxi

224 Cold urticaria occurred in all affected subjects.

225 c IgE to Na-ASP-2 that result in generalized urticaria on vaccination with recombinant Na-ASP-2.

226 ely event such as acute asthma exacerbation, urticaria or anaphylaxis, or an exacerbation of allergic

227 .001): (1) elevation of BST, (2) absence of urticaria or angioedema during anaphylaxis, (3) time int

228 The absence of urticaria or angioedema in severe reactions to Hymenopte

229 Some patients who achieved well-controlled urticaria or complete response sustained response throug

230 angioedema patients with chronic spontaneous urticaria or hereditary angioedema were repeatedly asked

231 ger threshold testing (in patients with cold urticaria or symptomatic dermographism) and/or a careful

232 skin reactions manifesting with angioedema, urticaria, or both have been distinguished: NSAID-exacer

233 nic spontaneous urticaria, chronic inducible urticaria, or both who showed complete response to omali

234 n patients with cholinergic urticaria, solar urticaria, or pressure urticaria).

235 ed MC in normal neck skin in anaphylaxis and urticaria patients with elevated sBT.

236 e in UAS7 values reflected change in chronic urticaria patients' quality of life impairment.

237 UAS7 values reflected chronic urticaria patients' quality of life impairment.

238 kin samples derived from chronic spontaneous urticaria patients.

239 on of ISM without accompanying skin lesions [urticaria pigmentosa (UP)] are lacking.

240 and chymase by mast cells of a patient with urticaria pigmentosa and aggressive systemic mastocytosi

241 Urticaria pigmentosa and mast cell mediator release symp

242 cell infiltration-related symptoms including urticaria pigmentosa and organomegaly (P < .02).

243 differed significantly between patients with urticaria pigmentosa and those with diffuse cutaneous (P

244 ween patients with and without osteoporosis, urticaria pigmentosa or anaphylaxis, respectively (P < 0

245 thic" anaphylaxis who did not exhibit either urticaria pigmentosa or the characteristic bone marrow b

246 mL) were as follows: controls, 176 (n = 60); urticaria pigmentosa without systemic involvement, 194 (

247 the typical maculopapular cutaneous lesions (urticaria pigmentosa) should be subdivided into 2 varian

248 gen C-telopeptide, hip bone mineral density, urticaria pigmentosa, and alcohol intake are easy to col

249 e), low hip bone mineral density, absence of urticaria pigmentosa, and alcohol intake at the time of

250 phylaxis, documented hypotension, absence of urticaria pigmentosa, and normal SBT levels.

251 son, acne vulgaris, bacterial skin diseases, urticaria, pruritus, scabies, cellulitis, and alopecia a

252 umab vs placebo at week 28 using the Chronic Urticaria Quality of Life (CU-Q2oL) questionnaire.

253 ) Dermatology Life Quality Index and Chronic Urticaria Quality of Life Questionnaire scores were 9.1

254 elated with sizes of SPT (erythema: r=0.645, urticaria: r=0.657).

255 active capacity of CU sera was evaluated and urticaria-related symptoms were assessed by both UCT and

256 Acute and chronic urticaria represent syndromes caused by a variety of tri

257 Chronic urticaria resolved in 43 patients, with a rate of resolu

258 Type 1 hypersensitivity reactions, including urticaria, rhinitis and asthma.

259 The most frequently reported symptoms were urticaria, rhinitis, dyspnoea and cough.

260 pruritus, alopecia areata, decubitus ulcer, urticaria, scabies, fungal skin diseases, impetigo, absc

261 ions that underlie atopic conditions such as urticaria, seasonal allergy, asthma and anaphylaxis.

262 mographism, cold urticaria, delayed-pressure urticaria, solar urticaria, heat urticaria, vibratory an

263 rmined history (in patients with cholinergic urticaria, solar urticaria, or pressure urticaria).

264 were conducted of outpatients treated at an urticaria specialist center of a university hospital.

265 ess disease control in patients with chronic urticaria (spontaneous and inducible).

266 24 weeks in patients with chronic idiopathic urticaria/spontaneous urticaria (CIU/CSU) who remained s

267 Our understanding of distinct urticaria subtypes differentially responsive to targeted

268 remain a cornerstone of therapy, particular urticaria subtypes may also respond to novel therapies s

269 t is unclear whether patients with recurrent urticaria symptoms after discontinuation of omalizumab t

270 covers the definition and classification of urticaria, taking into account the recent progress in id

271 literature continues to describe subtypes of urticaria that may be differentially responsive to parti

272 We followed a pediatric cohort with chronic urticaria that presented with hives lasting at least 6 w

273 However, the non-remission rate of urticaria that was treated with a standard dose of antih

274 is approximately 10% and for aspirin-induced urticaria the prevalence varies from 0.07% to 0.2% of th

275 ion typically involves the skin (generalized urticaria), the respiratory tract (cough, wheeze, strido

276 ingestion of mammalian meat and ranged from urticaria to anaphylaxis.

277 up-dosing was without sedation and supports urticaria treatment guidelines.

278 rrhoea (three patients [4%] vs one [2%]) and urticaria (two [3%] vs none), and no life-threatening to

279 ses that include MC-driven disorders such as urticaria, type I allergies, and mastocytosis as well as

280 recurrent anaphylaxis, angioedema, or acute urticaria underwent spirometry, exhaled nitric oxide, qu

281 g allergies, eczema, food allergy, rhinitis, urticaria, venom allergy and other probable allergic dis

282 ed-pressure urticaria, solar urticaria, heat urticaria, vibratory angioedema, cholinergic urticaria,

283 Duration of chronic urticaria was 5.5 months.

284 or almost daily (>4 days a week) presence of urticaria was defined as 'chronic persistent urticaria'

285 Urticaria was observed in QGE031- and placebo-treated su

286 One case of urticaria was observed on day 3 after the second dose of

287 ld or younger by one year after the onset of urticaria, was significantly lower than that of patients

288 d angioedema does not typically present with urticaria/weals and does not respond to conventional age

289 Response was defined as well-controlled urticaria (weekly Urticaria Activity Score [UAS7] </= 6)

290 linical records of patients with spontaneous urticaria were extracted.

291 f large populations of children with chronic urticaria were reported in the past year; one dealing wi

292 inflammatory skin diseases including chronic urticaria which is associated by increased IL-31 serum l

293 These results implicate CRH-R in chronic urticaria, which is often exacerbated by stress.

294 effective and safe in patients with chronic urticaria who have benefited from initial omalizumab tre

295 s with moderate-to-severe chronic idiopathic urticaria who remained symptomatic despite H-antihistami

296 screening accuracy to identify patients with urticaria with insufficiently controlled disease was fou

297 t encountered anaphylaxis with one NSAID and urticaria with other NSAIDs, and the last patient had an

298 We describe 2 patients having neutrophilic urticaria with systemic inflammation (NUSI) without know

299 us tissue disorders (eg, rash, pruritus, and urticaria) with insulin glargine.

300 taneous urticaria (CSU) is the recurrence of urticaria without an apparent trigger.